Sun Pharma board meeting scheduled for May 22, 2026 to approve Q4 and FY26 audited standalone and consolidated financial results.
Board to consider recommendation of final dividend for FY 2025-26 subject to shareholder approval at AGM.
Trading window closed from April 1, 2026 until May 24, 2026 in compliance with insider trading regulations.